

Cubist Pharmaceuticals

[View the current Cubist Pharmaceuticals Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/3117-Cubist+Pharmaceuticals.html)

(<http://www.bioportfolio.com/bi corporate/3117-Cubist+Pharmaceuticals.html>)

Contact Details:

65 Hayden Avenue

Lexington

MA

02421

United States of America

Tel: (781) 860-8660

Fax: (781) 861-0566

Email:

Cubist Pharmaceuticals Incorporated is a drug company focused on the discovery, development and commercialization of novel drugs to treat infections. Daptomycin, the Company's in-licensed lead product, is a unique agent with bactericidal activity that addresses the critical need for new antibiotics with potent activity against life threatening infections. Cubist Pharmaceuticals began Phase III clinical trials of intravenous daptomycin for complicated skin and soft tissue infections and also began a Phase II clinical trial for bacteremia in February of 1999. Cubist is also applying its VITA-TM- technology to validate unique targets and to build assays to identify additional novel compounds with a broad spectrum of activity against life-threatening infectious organisms such as methicillin resistant STAPHYLOCOCCUS AUREUS (MRSA) and vancomycin resistant enterococci (VRE).

Recent Publications by Cubist Pharmaceuticals:



- [Intraperitoneal daptomycin used to successfully treat vancomycin-resistant enterococcus peritonitis.](#)
Danish studies of traffic accidents at priority intersections have shown a... 17th November, 2009
Alabama Infectious Disease Center Nephrology Consultants, LLC Huntsville,- Perit Dial Int. 2009 Nov-Dec;29(6):671-3.
- [Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies.](#)
This review summarizes the in vitro and animal model data available on... 15th October, 2009
Cubist Pharmaceuticals Inc, Lexington, MA 02421, USA.- J Antimicrob Chemother. 2009 Dec;64(6):1130-8. Epub 2009 Oct 12. ([DOI Direct Link](#))
- [Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions.](#)
The decrease in vancomycin treatment efficacy that is accompanying... 10th October, 2009

- Cubist Pharmaceuticals, Lexington, MA, USA.- Lancet Infect Dis. 2009 Oct;9(10):617-24. ([DOI Direct Link](#))
- [Retrospective review of the use of daptomycin for diabetic foot infections.](#)
*The increase in antibiotic resistance has led to a search for alternative...*1st October, 2009
Cubist Pharmaceuticals, Lexington, Massachusetts, USA.- J Wound Care. 2009 Sep;18(9):396-400.
 - [Safety and efficacy of daptomycin in the treatment of osteomyelitis: results from the CORE Registry.](#)
*Antibiotic safety is a major determinant in osteomyelitis therapy. Limited...*1st October, 2009
Cubist Pharmaceuticals, Lexington, MA 02421, USA.- J Chemother. 2009 Aug;21(4):414-20.
 - [Safety and clinical outcomes when utilizing high-dose \(> or =8 mg/kg\) daptomycin therapy.](#)
*BACKGROUND: Daptomycin is approved for the treatment of skin and...*25th September, 2009
Cubist Pharmaceuticals Inc., Lexington, MA 02421, USA.- Ann Pharmacother. 2009 Jul;43(7):1211-9.
Epub 2009 Jul 7. ([DOI Direct Link](#))
 - [Daptomycin: mechanisms of action and resistance, and biosynthetic engineering.](#)
*Daptomycin is a lipopeptide antibiotic used clinically to treat infections...*31st July, 2009
Discovery Biology, Cubist Pharmaceuticals, Inc., 65 Hayden Avenue,- Curr Opin Chem Biol. 2009
Apr;13(2):144-51. Epub 2009 Mar 19. ([DOI Direct Link](#))
 - [Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience \(CORE\).](#)
*Enterococcal infections are a common cause of nosocomial bloodstream...*26th June, 2009
Cubist Pharmaceuticals, Inc., 65 Hayden Avenue, Lexington, MA 02421, USA.- Int J Antimicrob
Agents. 2009 Jun;33(6):543-8. Epub 2009 Feb 6. ([DOI Direct Link](#))
 - [Chapter 20. Biosynthesis and genetic engineering of lipopeptides in Streptomyces roseosporus.](#)
*Daptomycin is an acidic cyclic lipopeptide antibiotic approved for...*24th June, 2009
Cubist Pharmaceuticals Inc, Lexington, Massachusetts, USA.- Methods Enzymol. 2009;458:511-31. ([DOI Direct Link](#))
 - [The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas.](#)
*BACKGROUND: Results from previous trials suggest that daptomycin may...*12th May, 2009
Clinical Research, Cubist Pharmaceuticals, Lexington, MA 02421, USA.- Int J Clin Pract. 2009
Mar;63(3):368-75. ([DOI Direct Link](#))
 - [A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria.](#)
*BACKGROUND: Methicillin-susceptible and -resistant (MRSA) Staphylococcus...*8th May, 2009
Cubist Pharmaceuticals, Inc., Lexington, MA 02421, USA.- Int J Clin Pract. 2008 Sep;62(9):1455-64.
Epub 2008 Jul 25. ([DOI Direct Link](#))
 - [Renaissance in antibacterial discovery from actinomycetes.](#)
*The soil actinomycetes have been important sources of antibiotics, but...*31st January, 2009
Drug Discovery and Evaluation, Cubist Pharmaceuticals, Inc., 65 Hayden- Curr Opin Pharmacol. 2008
Oct;8(5):557-63. Epub 2008 Jun 3. ([DOI Direct Link](#))
 - [Non-ribosomal peptide synthetase module fusions to produce derivatives of daptomycin in Streptomyces roseosporus.](#)
*Genetic engineering has been applied to reprogramme non-ribosomal peptide...*10th October, 2008
Cubist Pharmaceuticals Inc., 65 Hayden Avenue, Lexington, MA 02421, USA.- Microbiology. 2008
Sep;154(Pt 9):2872-80. ([DOI Direct Link](#))
 - [Outpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry.](#)
*AIM: To compare and contrast the characteristics and clinical outcomes of...*1st October, 2008
Cubist Pharmaceuticals, Inc., Lexington, MA 02421, USA.- Int J Clin Pract. 2008 Aug;62(8):1183-7. ([DOI Direct Link](#))
 - [Biosynthesis and genetic engineering of lipopeptide antibiotics related to daptomycin.](#)
*Daptomycin is a clinically important antibiotic approved for the treatment...*23rd September, 2008
Cubist Pharmaceuticals, Inc., 65 Hayden Avenue, Lexington, Massachusetts- Curr Top Med Chem.
2008;8(8):618-38.

Press Releases on Cubist Pharmaceuticals:

Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference	25th November, 2009	Ardea Biosciences, Inc.	SAN DIEGO, Nov. 25 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that Barry D. Quart, Pharm.D., president and chief executive officer, will present at the Piper
iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering	25th November, 2009		DELFT, The Netherlands and JOHANNESBURG, November 25 /PRNewswire/ -- iThemba Pharmaceuticals' service division and Pyxis Discovery announced today that they have signed a collaborative agreement
Reportlinker Adds Cell/Tissue Culture Supplies - A Global Market Perspective	25th November, 2009	Reportlinker	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Cell/Tissue Culture Supplies - A Global Market Perspective http://www
Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis	25th November, 2009	Reportlinker	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Intranasal Drug Delivery - US Market Trends & Analysis http://www
Reportlinker Adds Pain Management - Global Trends	25th November, 2009	Reportlinker	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Pain Management - Global Trends http://www.reportlinker.com/p0164220/Pain

BioNews Results for Cubist Pharmaceuticals



- [Stock research report available on Cubist Pharmaceuticals \(NASDAQ:CBST\) from SmarTrend Analytics](#)
TradingMarkets: Nov 19 2009 7:53PM Matching: cubist pharmaceuticals
- [Research and Markets: Antibiotics - Global Trends Report: Geographic Coverage and Vertical...](#)
Forbes.com: Nov 18 2009 4:03PM Matching: cubist pharmaceuticals
- [Research and Markets: Antibiotics - Global Trends Report: Geographic Coverage and Vertical Market Analysis](#)
PR inside: Nov 18 2009 3:33PM Matching: cubist pharmaceuticals
- [Research and Markets: Antibiotics - Global Trends Report: Geographic Coverage and Vertical Market Analysis](#)
Reuters: Nov 18 2009 3:25PM Matching: cubist pharmaceuticals
- [Cubist Pharmaceuticals To Present At Lazard Capital Markets 6th Annual Healthcare Conference At](#)

1:45 PM ET

RTTNews.com: Nov 18 2009 4:58PM Matching: cubist pharmaceuticals

- [Research and Markets: Antibiotics - Global Trends Report: Geographic Coverage and Vertical Market Analysis](#)

Business Wire via Yahoo!: Nov 18 2009 3:19PM Matching: cubist pharmaceuticals

- [Research and Markets: Antibiotics - Global Trends Report: Geographic Coverage and Vertical Market Analysis](#)

Yahoo! Canada: Nov 18 2009 3:19PM Matching: cubist pharmaceuticals

- [Research and Markets: Antibiotics - Global Trends Report: Geographic Coverage and Vertical Market Analysis](#)

Business Wire UK: Nov 18 2009 3:12PM Matching: cubist pharmaceuticals

- [Research and Markets: Antibiotics - Global Trends Report: Geographic Coverage and Vertical Market Analysis](#)

Business Wire: Nov 18 2009 3:08PM Matching: cubist pharmaceuticals

- [Cubist Pharmaceuticals Down 6.8% Since SmarTrend's Sell Recommendation](#)

TradingMarkets: Nov 13 2009 7:36PM Matching: cubist pharmaceuticals

- [Cubist Pharmaceuticals Has Risen Above A Trading Range](#)

RTTNews.com: Nov 12 2009 7:03PM Matching: cubist pharmaceuticals

- [Options Boil on Biotech Buyout Rumors](#)

CNBC: Nov 12 2009 10:30PM Matching: cubist pharmaceuticals

- [Key RNAi-Based Drugs in the Clinic](#)

GenomeWeb: Nov 11 2009 8:32PM Matching: cubist pharmaceuticals

- [The Boston Globe names Cubist to Globe 100's Top Places to Work '09](#)

Individual.com: Nov 9 2009 1:09PM Matching: cubist pharmaceuticals

- [Alnylam to Webcast R&D Day on Thursday, November 12, 2009](#)

Pharma Live: Nov 9 2009 10:10PM Matching: cubist pharmaceuticals

Cubist Pharmaceuticals Clinical Trials:



- [Safety and Efficacy Study of Daptomycin in Pediatric Subjects \(7-17 Years\) With Skin and Skin Structure Infections](#)

Cubist Pharmaceuticals Patents:



- 7527807- [Compositions and methods for increasing the oral absorption of antimicrobials](#)
- 6333344- [Prolines as antimicrobial agents](#)
- 6221640- [Enterococcal aminoacyl-trna synthetase proteins, nucleic acids and strains comprising same](#)

- 6174713- [Candida cytoplasmic tryptophanyl-tRNA synthetase proteins, nucleic acids and strains comprising same](#)
- 6153645- [Heterocycles as antimicrobial agents](#)
- 5912140- [Recombinant pneumocystis carinii aminoacyl tRNA synthetase genes, tester strains and assays](#)
- 5885815- [Candida isoleucyl-tRNA synthetase proteins, nucleic acids and strains comprising same](#)
- 5871987- [Candida tyrosyl-tRNA synthetase proteins, nucleic acids and strains comprising same](#)
- 5824657- [Aminoacyl sulfamides for the treatment of hyperproliferative disorders](#)
- 5801013- [Helicobacter aminoacyl-tRNA synthetase proteins, nucleic acids and strains comprising same](#)
- 5798240- [Recombinant mycobacterial methionyl-tRNA synthetase genes and methods of use therefore](#)
- 5759833- [Human isoleucyl-tRNA synthetase proteins, nucleic acids and tester strains comprising same](#)
- 5756327- [Recombinant mycobacterial isoleucyl-tRNA synthetase genes, tester strains and assays](#)
- 5726195- [Aminoacyl adenylate mimics as novel antimicrobial and antiparasitic agents](#)
- 5656470- [Recombinant mycobacterial seryl-tRNA synthetase genes, tester strains and assays](#)
- 6348482- [Catechols as antimicrobial agents](#)
- 6417217- [Prolines as antimicrobial agents](#)
- 6436694- [Regulable gene expression in gram-positive bacteria](#)
- 7408025- [Lipopeptides as antibacterial agents](#)
- 7335726- [Lipopeptide stereoisomers, methods for preparing same and useful intermediates](#)
- 7335725- [Lipopeptides as antibacterial agents](#)
- 7262268- [Lipopeptide stereoisomers, methods for preparing same, and useful intermediates](#)
- 7235651- [Genes and proteins involved in the biosynthesis of lipopeptides](#)
- 6911525- [Lipopeptides as antibacterial agents](#)
- 6852689- [Methods for administration of antibiotics](#)
- 6846625- [Method for identifying validated target and assay combination for drug development](#)
- 6794490- [Lipopeptides as antibacterial agents](#)
- 6784203- [Cytokine production inhibitors](#)
- 6696412- [High purity lipopeptides, Lipopeptide micelles and processes for preparing same](#)
- 6579894- [Prolines as antimicrobial agents](#)
- 6475726- [Method for identifying validated target and assay combinations for drug development](#)
- 6468967- [Methods for administration of antibiotics](#)
- 5629188- [Human alanyl-tRNA synthetase proteins, nucleic acids and tester strains comprising same](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

